WuXi AppTec H1 2026: Revenue RMB 28.9B, Up 38.9%; Full-Year Guidance Raised Across the Board

Adjusted non-IFRS net profit of RMB 11.57B, up 83.2% YoY; backlog of RMB 66.4B, up 25.2%; full-year revenue guidance raised to RMB 58.5–60.5B. Attributable net profit topped RMB 10B in H1 for the first time.

On August 3, WuXi AppTec (603259.SH / 2359.HK) reported H1 2026 results: total revenue of RMB 28.90B, up 38.9% YoY; continuing-operations revenue up 48.0%; adjusted non-IFRS net profit of RMB 11.57B, up 83.2%, with net margin up 9.7 ppts to 40.0%; and attributable net profit of RMB 11.08B, up 29.4% — the first time H1 attributable profit has exceeded RMB 10B.

As of end-June 2026, continuing-operations backlog stood at RMB 66.43B, up 25.2% YoY; adjusted operating cash flow was RMB 9.98B, up 41.3%. By segment, Chemistry business revenue was RMB 24.99B (+53.3%), still the core driver — small-molecule D&M (process R&D and manufacturing) revenue reached RMB 14.99B, up 72.7%; the TIDES business (oligonucleotides and peptides) earned RMB 7.26B, up 44.3%, with ~45% full-year growth expected. Testing business revenue was RMB 2.48B (+31.5%) and Biology RMB 1.39B (+11.2%).

On the strength of these results, the company raised all its 2026 guidance: full-year revenue from RMB 51.3–53.0B to RMB 58.5–60.5B; continuing-operations revenue growth from 18–22% to 35–39%; capex from RMB 6.5–7.5B to RMB 7.5–8.5B (early-starting a new Changzhou base); and adjusted free cash flow from RMB 10.5–11.5B to RMB 13.5–14.5B.

Chairman and CEO Dr. Ge Li commented: "Thanks to the greater success of multiple client products, our unique CRDMO business model and excellent execution, revenue, profit and cash flow all grew strongly." He also addressed the US DoD 1260H listing: "The erroneous designation lacks factual basis and legal support. We have taken legal action; the litigation is ongoing, and we are confident a fair judicial review will vindicate the facts."

The same day, the company unveiled a 2026 A-share employee stock ownership plan covering up to 4,000 managers and core technical staff, granting up to 9.70M shares at RMB 103.08 per share from long-term incentive funds of up to RMB 1B, with vesting tied to 2026 revenue targets. An interim dividend of RMB 5.1 per 10 shares (RMB 1.51B total) was also declared. On ESG, the company retained its MSCI AAA rating and was included in the FTSE4Good Index Series for the fourth consecutive year.